Patients in the phase II study were prescreened for FGFR2 status by next-generation sequencing (NGS) with the Malignant Neoplasms Multi-Gene Analysis Kit (Suzhou Geneplus Biomedical Engineering Co., Suzhou, China) at the central laboratory on archival formalin-fixed and paraffin-embedded tumor samples or fresh tumor samples; FGFR2 status reports based on DNA sequencing performed within 2 years could also be used; a relative abundance of variant allele of >5.3% was used to define FGFR2 fusions or rearrangements (the lower boundary of frequency detected by FMI central laboratory in FIGHT-202 study).